Status:
UNKNOWN
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
Lead Sponsor:
University Health Network, Toronto
Conditions:
Epstein-Barr Virus Infections
Post-transplant Lymphoproliferative Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Post-transplant lymphoproliferative disorders (PTLD) can present as a type of malignancy that limits patient and graft survival after solid organ transplantation. Many early PTLDs are driven by the Ep...
Detailed Description
Previous studies have shown that EBV D+/R- lung transplant patients have a high rate of post-transplant lymphoproliferative disease up to 22%. Various methods have been proposed to decrease the risk o...
Eligibility Criteria
Inclusion
- Age \>=18 years
- Listed for single or double lung transplantation
- EBV (EBNA IgG and/or VCA IgG) seronegative (tested within the last 12 months)
Exclusion
- EBV seropositivity at any time prior to transplant
- History of Cancer (eg, lymphoma)
- History of receiving rituximab or allergy to rituximab
- Underlying immunodeficiency (eg, common variable immune deficiency)
- Unable or unwilling to comply with study procedures
Key Trial Info
Start Date :
July 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 7 2023
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04507477
Start Date
July 7 2020
End Date
February 7 2023
Last Update
August 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network, Toronto General Hospital, Multi-Organ Transplant
Toronto, Ontario, Canada, M5G2N2